Most sites treat the site qualification visit as a tour with a few extra questions attached. The monitor walking through your clinic is running a scored evaluation that gets typed into a report the same afternoon. That report follows your site into the sponsor's next study decision, whether or not the study in front of you ever gets awarded.
37%
of enrolled sites underperform their own enrollment target (Tufts CSDD)
7–14 days
time to first patient at top-performing sites, vs. ~30 days average (Applied Clinical Trials Online, Clincove)
What the Visit Is Actually Deciding
By the time a sponsor or CRO schedules a site qualification visit (SQV), they already believe your patient population can support the study. That belief is why you got the visit in the first place. The SQV tests something different: whether the operation behind the PI can execute the protocol without creating problems downstream.
Our guide on how research sites actually get selected for clinical trials covers the five domains sponsors weigh before the SQV is even scheduled. This guide picks up where that leaves off: the specific steps that turn a qualification visit into a strong evaluation instead of a stressful afternoon, and what to do once the monitor's report comes back.
The gap between sites that treat the SQV as a formality and sites that treat it as a real evaluation shows up fast. It shows up in time to first patient, and it shows up in whether the sponsor's next study inquiry comes to your site at all.
The Notice-to-Visit Window: What to Do With the Time You Get
Notice for an SQV typically arrives with enough lead time to prepare properly, and most sites spend that window on the wrong things. Facility tidying and last-minute binder assembly feel productive. They do not move the numbers a monitor is actually scoring.
The moment notice arrives, name one person as the internal SQV lead, even at a site where the PI normally owns everything. That person's job for the rest of the window is threefold: request the visit agenda in writing so the team knows what gets covered and in what order, block every named attendee's calendar for the full visit window rather than a partial overlap, and start the document pull immediately instead of the week before.
A site that starts this process on day one of notice walks into the visit from a rehearsed position. A site that starts on day one before the visit is working from a checklist under time pressure, and monitors can generally tell the difference.
The Document Binder: What Actually Needs to Be Ready
The binder does not need to be flawless at the SQV stage. It needs to exist, be current, and let the monitor find any single document in under a minute. Five categories cover most of what gets checked.
Delegation of authority log, signed and current
Every listed team member should match who is actually in the room. A log with names who left the site a year ago is a bigger flag than a log with fewer names on it.
CVs, licenses, and GCP training certificates
For the PI, sub-investigators, and coordinators named on the delegation log. Current licensure and a GCP certificate that has not lapsed are the two items monitors check first.
IRB documentation and an SOP index
A short index that points to where each SOP lives beats a stack of undated policies with no way to confirm which version is active.
A one-page prior performance summary
Enrollment rate against target and screen fail rate on your two or three most comparable prior studies, with the protocol type noted for context. A site that can hand over this page unprompted stands apart from one that describes past performance from memory.
Budget and contract readiness notes
A short note on your site's typical internal review timeline for a contract and budget, so the monitor is not left guessing how long that stage will add to activation.
Our self-assessment across the six domains sponsors check is built to surface gaps in this binder before a visit is on the calendar, not during it.
Briefing the Team, Not Just the PI
Monitors ask the coordinator protocol questions directly: eligibility criteria detail, the visit schedule, how the primary endpoint is defined. A coordinator who answers confidently, without reaching for the protocol document, signals a site that runs trials day to day rather than one reading about this study for the first time in the room.
A short mock walkthrough in the days before the visit, with someone on staff playing the monitor and asking the questions the protocol is likely to prompt, closes most of that gap. It costs less than an hour and it is the single highest-leverage prep step most sites skip.
The PI's presence for the full visit window matters as much as anything in the binder. If the PI is unavailable for any portion without advance notice to the monitor, it reads as a signal that substantive protocol decisions get delegated further than the sponsor is comfortable with. Front desk and facilities staff should also know the visit is happening, so it does not create confusion for other patients on the schedule that day.
Talk through your study with our team.
Book a free consultation to discuss your enrollment goals and whether our guaranteed recruitment model is a good fit for your study and site. No commitment required.
Book a Free ConsultationMost Findings Are Correctable. The Response Is What Gets Judged.
A qualification visit rarely ends in an outright pass or fail. Monitors more often issue a conditional approval: the site moves forward pending correction of specific items, on a defined timeframe the sponsor sets. Expired licenses, gaps in GCP training records, and an incomplete regulatory binder are common findings, and every one of them is fixable.
What is not correctable after the fact is a disorganized response. Assign an owner for each finding the same day the report arrives, set an internal deadline shorter than the one the sponsor gave you, and reply in writing once every item is closed rather than trickling updates in one at a time.
The finding itself is one data point. How fast and how organized the correction looks is the next one, and it is the one the sponsor's team remembers going into activation.
What a Strong SQV Buys You Later
None of this is about impressing a monitor for one afternoon. A well-run qualification visit becomes part of the performance record a sponsor pulls the next time your site is under consideration, alongside enrollment rate and screen fail data from prior studies.
Sites that build SQV preparation into a standing process, rather than reacting fresh each time, carry that record into the next feasibility questionnaire with evidence instead of a general impression. It is not a bigger site that gets flagged as preferred. It is the site that has already answered the questions before they are asked.
Sites weighing whether a specific study is a realistic fit before that first visit gets scheduled can check if a study qualifies for a randomization commitment. An enrollment guarantee attached to the study lowers the risk a sponsor is weighing at every stage of the selection process, the SQV included.
Phase 3, vTv Therapeutics T1D
$1,818 CPP
11 randomized patients · $20,000 investment · 3 site locations
Read the case studyPediatric RSV Vaccine, Blue Lake Biotechnology
$3,000 CPP
10 randomized patients · $30,000 investment · 3 site locations
Read the case studyA Rehearsed Site Looks Different From an Improvising One
A monitor sitting across from a coordinator can generally tell within the first few questions whether the team prepared or is reconstructing the protocol on the spot. Neither outcome is about site size or facility polish. It is about whether the site turned notice of a visit into a rehearsed process ahead of time.
The sites that keep getting invited back are not necessarily the ones with the cleanest first visit. They are the ones whose response to a finding was fast and organized, and whose next SQV looked like a repeatable process instead of a first attempt.
None of the steps in this guide require new headcount or new systems. They require deciding, once, that qualification visit prep happens on a checklist instead of in the days right before the monitor arrives.
Sources: Tufts Center for the Study of Drug Development (site-level enrollment performance, 151 Phase II/III trials across roughly 16,000 sites, 2008-2010: 37% of enrolled sites under-enroll); Applied Clinical Trials Online, Clincove (site activation and time-to-first-patient benchmarks); Clinical Enroll (first-party CPP data from published case studies, clinicalenroll.com/case-studies).